Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Getting new auth cookie, if you see this message a lot, tell someone!

Hypertension

  • You have access
    The role of multiple risk factors in cardiovascular morbidity and mortality
    Ray W. Gifford, MD
    Cleveland Clinic Journal of Medicine May 1993, 60 (3) 211-218;

    BACKGROUND Cardiovascular disease remains the leading cause of death in the United States.

    OBJECTIVE To identify important modifiable cardiovascular risk factors and appropriate interventions.

    DISCUSSION The three most important modifiable risk factors are hypertension, cigarette smoking, and dyslipidemia. Systolic hypertension poses a greater risk than diastolic, but the prognostic significance of diastolic blood pressure may have been underestimated. When a smoker quits, the cardiovascular risk soon approaches that of the nonsmoker. Cardiovascular risk increases progressively with elevations of the serum total cholesterol level above 200 mg/dL. Recently identified risk factors include hyperinsulinemia and left ventricular hypertrophy.

    CONCLUSION Each patient deserves an evaluation of cardiovascular risk followed by education about and therapy for those risk factors that can be changed. When more than one risk factor is present, as is often the case, the increase in risk may be synergistic rather than additive.

  • You have access
    Current hypertension management: separating fact from fiction
    Marvin Moser, MD
    Cleveland Clinic Journal of Medicine January 1993, 60 (1) 27-37;

    Speculations that have led many physicians to abandon the use of diuretics have not proven to be of clinical relevance in most instances.

  • You have access
    Primary pulmonary hypertension, then and now: 28 years of experience
    Benjamin D. Robalino, MD and Douglas S. Moodie, MD, MS
    Cleveland Clinic Journal of Medicine July 1992, 59 (4) 411-417;

    Patients with PPH are presenting at earlier stages of the disease, have fewer complications during cardiac catheterization, and probably survive longer after diagnosis than patients seen several decades ago.

  • You have access
    Adrenergic agents: clinical trials and experiences
    Alan Bakst, PhannD and Lennart Hansson, MD, PhD
    Cleveland Clinic Journal of Medicine May 1992, 59 (3) 248-254;

    Different beta blockers have different effects on cardiac output and heart rate, and some may diminish detrimental arterial changes induced by hypertension. A long-term preventive effect against coronary artery disease remains to be demonstrated.

  • You have access
    The hemodynamic effects of adrenergic blocking agents
    Alan Bakst, PharmD and Per Lund-Johansen
    Cleveland Clinic Journal of Medicine March 1992, 59 (2) 193-200;

    Alpha-1 blockers may suit patients with active life-styles, peripheral vascular disorders, or high blood-cholesterol levels, while beta blockers are useful in tachycardia, palpitations, or angina pectoris. An overview of the pharmacologic qualities and numerous clinical applications of these agents.

  • You have access
    Treating hypertension to prevent coronary disease
    Norman M. Kaplan, MD
    Cleveland Clinic Journal of Medicine September 1991, 58 (5) 432-443;

    Past successes and failures in treating hypertension suggest ways to provide better overall therapy and reduce the incidence of coronary heart disease.

  • You have access
    Alpha- and beta-blocking agents: pharmacology and properties
    B.N.C. Prichard
    Cleveland Clinic Journal of Medicine July 1991, 58 (4) 337-350;

    Continued investigations into the multiple effects of certain alpha and beta blockers may provide clues to more effective treatment of hypertension.

  • You have access
    Tailoring antihypertensive therapy in 1991
    Cleveland Clinic Journal of Medicine May 1991, 58 (3) 277-284;

    The trend is toward individualized treatment and away from rigid stepped care.

  • You have access
    The Telelab personal blood pressure transmitter: accurate and reliable home monitoring for hypertensive patients
    Donald G. Vidt, MD, Kennith Bolen, Ray W. Gifford, MD and Sharon Vanderbrug Medendorp
    Cleveland Clinic Journal of Medicine January 1991, 58 (1) 28-32;

    A home blood pressure recording device that can transmit data by phone is accurate and convenient.

  • You have access
    The role of adrenergic drugs in antihypertensive therapy
    Harold D. Itskovitz, MD
    Cleveland Clinic Journal of Medicine January 1991, 58 (1) 79-93;

    The clinical effects of drugs in the adrenergic class can be predicted by the location of the alpha or beta receptors that the drug activates or inhibits.

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire